ClinicalTrials.gg
CompletedNCT01715324Updated Jan 11, 2022

Adjuvant Growth Therapy in in Vitro Fertilization

A Phase 4 interventional study of Adjuvant Growth Hormon in Infertility, sponsored by Clinique Ovo. Completed at 1 site in Canada. Open to female participants aged 35 Years to 42 Years. Per ClinicalTrials.gov, last updated 2022-01-11.

Sponsored by Clinique Ovo · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
288
Allocation
Randomized
Ages
35 Years to 42 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies in Infertility by Clinique Ovo — none open to participants now, none under way, none of them phase 3. Infertility · Clinique Ovo.

Started
2014
the only one that year
Phase 4
2 of 20
none open now
Registered
6th of 20
by date

Among the 20 studies in Infertility by Clinique Ovo, this one is the only one that started in 2014, is one of 2 in phase 4, and was the 6th registered.

Infertility

2,089 studies on the registry are indexed under Infertility; 355 are open to participants now.

Browse Infertility studies →

Open to participants now

None of the 20 studies in Infertility by Clinique Ovo is open now. The open studies under Infertility, anywhere →

Where they have run

Who these studies take

Of the 233 Infertility studies recruiting now, 43 (18%) set no upper age limit and 184 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.

This study: 35 Years to 42 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 20 studies in Infertility by Clinique Ovo as a file.
02

Study summary

In an In Vitro Fertilization (IVF) cycle super ovulating drugs (gonadotropins) are usually taken to stimulate the ovaries to produce more than one egg. In Vitro Fertilization protocols are constantly under review in order to improve the recruitment of the follicles, which contain the eggs, whilst minimizing the doses of gonadotrophins required, with the ultimate aim of increasing the live birth rate.

Read the detailed description

The addition of growth hormone, which is a biological hormone that can be synthetically produced, as a supplement to gonadotrophins in an In Vitro Fertilization cycle has been suggested as a way in which In Vitro Fertilization pregnancy rates may be increased.Growth hormone has been shown, in animal and human studies, to be important in the recruitment of follicles.However, to date, only a limited number of clinical studies have been performed in order to assess whether the addition of growth hormone can improve the probability of pregnancy in women undergoing ovarian stimulation for In Vitro Fertilization. As the total number of patients analysed in these studies was small it has not been possible to determine whether if there is any improvement the outcome of an In Vitro Fertilization cycle when a woman is given growth hormone therapy as a supplement during her treatment.

This goal of this study is to determine the effectiveness of using growth hormone therapy as a supplement to the administration of gonadotropins in an antagonist In Vitro Fertilization protocol.

03

Conditions studied

  • Infertility

Browse trials for

Keywords

  • In vitro fertilization
  • Antagonist protocol
  • Growth Hormone
04

Who can participate

Ages eligible
35 Years to 42 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women between the ages of 35 to 42
  • Primary or secondary infertility)

    • No previous treatment IVF cycle using the same proposed protocol
  • Negative pregnancy test at randomization (urine or blood)

Exclusion criteria

Exclusion Criteria:

  • to Saizen®
  • Simultaneous participation in another clinical trial
  • follicle stimulating hormone > 12 IU/L and/or anti-mullerian hormone \< 0.5 pg/ml
  • ≥ 35 kg/m2
  • Known risk of gestational diabetes
  • Administration of any medication three months prior to study enrolment
  • Positive results of screening for either partner for antibodies, (other than surface antibodies present after vaccination) or
  • Not able to communicate in French or English
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
288 participants (actual)

Study arms

  • Experimental
    Growth Hormon

    The participants randomized in the control group will be prescribed a regular antagonist IVF cycle with dose appropriate stimulation medication and will receive 2.5 mg of Adjuvant Growth Hormon (Saizen) daily via subcutaneous injections, from the beginning of the ovarian reserve stimulation until the day of the ovulation triggering.

    Drug: Adjuvant Growth Hormon

  • No intervention
    Control

    The participants randomized in the control group will be prescribed a regular antagonist IVF cycle with dose appropriate stimulation medication without Adjuvant Growth Hormon (Saizen).

Interventions

  • The treatment group will receive 2.5 mg of Saizen daily via subcutaneous injections, from the beginning of the ovarian reserve stimulation until the day of the ovulation triggering

    Also known as: Saizen

06

What researchers measure

Primary outcomes

  1. Clinical pregnancy rate

    To determine if the clinical pregnancy rate during the course of one treatment cycle in women receiving Growth Hormone daily in addition to gonadotropin-releasing hormone antagonist protocol is significantly higher than those receiving only gonadotropin-releasing hormone antagonist protocol (control group).

    Time frame: 7 weeks

Secondary outcomes

  1. Total dose of gonadotropins

    To evaluate the effectiveness of Growth Hormon adjuvant therapy in gonadotropin-releasing hormone antagonist protocol when compared to the control group.

    Time frame: 7 weeks

  2. Number of observed follicles

    To evaluate the effectiveness of Growth Hormon adjuvant therapy in gonadotropin-releasing hormone antagonist protocol when compared to the control group.

    Time frame: 7 weeks

  3. Number of mature (Metaphase II) oocytes retrieved

    To evaluate the effectiveness of Growth Hormon adjuvant therapy in gonadotropin-releasing hormone antagonist protocol when compared to the control group.

    Time frame: 7 weeks

  4. Oocyte morphology

    To evaluate the effectiveness of Growth Hormon adjuvant therapy in gonadotropin-releasing hormone antagonist protocol when compared to the control group.

    Time frame: 7 weeks

  5. Fertilization rate

    To evaluate the effectiveness of Growth Hormon adjuvant therapy in gonadotropin-releasing hormone antagonist protocol when compared to the control group.

    Time frame: 7 weeks

  6. Embryo morphology

    To evaluate the effectiveness of Growth Hormon adjuvant therapy in gonadotropin-releasing hormone antagonist protocol when compared to the control group.

    Time frame: 7 weeks

  7. Embryo cleavage rate

    To evaluate the effectiveness of Growth Hormon adjuvant therapy in gonadotropin-releasing hormone antagonist protocol when compared to the control group.

    Time frame: 7 weeks

  8. Number of embryos available

    To evaluate the effectiveness of Growth Hormon adjuvant therapy in gonadotropin-releasing hormone antagonist protocol when compared to the control group.

    Time frame: 7 weeks

  9. Number of supernumerary embryos available for cryopreservation

    To evaluate the effectiveness of Growth Hormon adjuvant therapy in gonadotropin-releasing hormone antagonist protocol when compared to the control group.

    Time frame: 7 weeks

  10. Implantation rate

    To evaluate the effectiveness of Growth Hormon adjuvant therapy in gonadotropin-releasing hormone antagonist protocol when compared to the control group.

    Time frame: 7 weeks

  11. Miscarriage rate

    To evaluate the effectiveness of Growth Hormon adjuvant therapy in gonadotropin-releasing hormone antagonist protocol when compared to the control group.

    Time frame: 40 weeks

  12. Live birth rate

    To evaluate the effectiveness of Growth Hormon adjuvant therapy in gonadotropin-releasing hormone antagonist protocol when compared to the control group.

    Time frame: 40 weeks

  13. Adverse side effects in women

    To evaluate the effectiveness of Growth Hormon adjuvant therapy in gonadotropin-releasing hormone antagonist protocol when compared to the control group.

    Time frame: 7 weeks

07

Study locations

1 site
  • Clinique Ovo
    Montreal, Quebec H4P 2S4, Canada
08

References and documents

Publications

  • Sood A, Mohiyiddeen G, Ahmad G, Fitzgerald C, Watson A, Mohiyiddeen L. Growth hormone for in vitro fertilisation (IVF). Cochrane Database Syst Rev. 2021 Nov 22;11(11):CD000099. doi: 10.1002/14651858.CD000099.pub4. PubMed 34808697 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2014 to primary completion in Jul 2021, 85 months.

Of 81 phase 4 interventional studies under Infertility, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 82. This study's 85 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2012
First posted
Oct 26, 2012
StartActual
Jun 25, 2014
Primary completionActual
Jul 2021
CompletionActual
Aug 2021
Last update
Jan 11, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 11, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01715324
Lead sponsor
Clinique Ovo
Collaborators
EMD Serono
Responsible party
Sponsor
First posted
Oct 26, 2012
Start date
Jun 25, 2014
Primary completion
Jul 2021
Completion
Aug 2021
Last update
Jan 11, 2022

Study contacts

Jacques Kadoch, MD
principal investigator · Clinique Ovo

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Growth Hormone

Start the discussion